Search results
Novel Bispecific in EGFR-Mutant Lung Cancer Boosts PFS After Targeted Agents
MedPage Today· 6 days agoChina-based trial may present a hurdle to FDA approval, however
GSK blood cancer drug nearly halves risk of death in late-stage trial | Honolulu Star-Advertiser
Honolulu Star-Advertiser· 5 days agoGSK’s multiple myeloma drug Blenrep nearly halved the risk of disease progression or death compared...
Allen Institute's cell lines could lead to new drugs for hypertrophic cardiomyopathy
FierceBiotech· 3 days agoHypertrophic cardiomyopathy, or HCM, is a common but potentially lethal heart disease. While...
Focusing on Reward a Solution to MS-Related Fatigue?
Medscape· 2 days agoInterventions that stimulate the reward system may be the most effective treatment for fatigue directly related to multiple sclerosis (MS), experts said....
GSK blood cancer drug nearly halves risk of death in late-stage trial
AOL· 5 days agoGSK's multiple myeloma drug Blenrep nearly halved the risk of disease progression or death compared to standard-of-care treatments for the incurable blood cancer, according to data from a late-stage ...
MS Med Nearly Eliminates Disease Activity on MRI
Medscape· 2 days agoA second-generation anti-CD40L monoclonal antibody suppresses multiple sclerosis (MS) disease activity on MRI to an uncommonly high degree, new trial data suggested. Researchers found a near ...
TEVA Stock Rises 135% in a Year: What's Driving the Recovery?
Zacks· 3 days agoTeva Pharmaceutical Industries Limited’s (TEVA Quick QuoteTEVA - Free Report) revenues have suffered...